Aclaris Alopecia Areata

What we are studying

This study is designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution (twice daily for 24 weeks) in subjects with stable patchy alopecia areata (AA). Subjects will receive one of the following: ATI-50002 Topical Solution, 0.46%, ATI-50002 Topical Solution, 0.12%, or Vehicle/Placebo Topical Solution. You will not know which group you will be in.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Clinical diagnosis of alopecia areata
  • Current episode of scalp hair loss of a minimum of 6 months and a maximum of seven years
  • Good general health

What is involved

  • Your participation will include 11 visits to the study center and will last about 28 weeks
  • Up to a maximum of 197 days
  • With a possibility of up to an additional 30 days for screening results to be received.

Compensation

$75.00 for each completed visit

Contact Information

Study Coordinator
DermAdvertising
Email
[email protected]
Phone
-3775
Principal Investigator
Amy McMichael, MD

дженерик виагра софт отзывы

таблетки повышающие потенцию для мужчин

bestseller-sales.com

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.